Medical Funding Professionals (MFP) is pleased to announce that Medical 21 has engaged MFP to implement the Capital Planning Valuation Strategy™ Co-Chaired by Scott Pantel of LSI and Stephen Brock of MFP in preparation of the company’s Regulation A+ offering.

Medical 21 is a developmental stage medtech company revolutionizing cardiac bypass surgery with an artificial graft that eliminates the need for saphenous vein grafts (SVGs) or the harvesting of other vessels from the body. Medical 21’s graft technology will not only reduce pain and vastly improve the recovery of heart bypass patients but also assist cardiac surgeons by reducing operating times. The graft provides the flexibility to perform bypass surgery either on the heart-lung bypass machine or “off-pump,” and eliminates costs associated with wound-related post-operative care and readmissions.

“Cardiovascular disease is the number one cause of death globally and surgeons need a better option for a complete revascularization procedure of the heart,” says Medical 21 founder Manny Villafaña. “By eliminating the need to harvest vessels from a patient’s arm, leg, and chest, surgical teams can save time and help patients who can then recover faster without additional scarring, pain, or post-op complications.”

In addition to preparing for clinical trials, Medical 21 is in the process of completing non-clinical testing required for regulatory submissions and establishing regulatory strategies to obtain EU and other government marketing authorizations. As Medical 21 gets set to undergo clinical trials, Villafaña considers Regulation A+ the next logical step on the road to commercialization.

“We see Reg A+ financing as the 21st century way of funding a company and bringing this life-changing solution to market,” continues Villafaña. “Despite having an accomplished career in the cardiac health space, Medical 21 is by far the company I’m most excited about because of its enormous potential to improve conditions for the millions of coronary artery heart bypass surgery patients.”

“We look forward to working with Medical 21,” says Medical Funding Professionals CEO Stephen Brock. “We all know about the devastating impacts of cardiovascular disease and how dangerous these bypass surgeries can be. Medical 21’s technology will revolutionize how these surgeries are conducted and we’re excited to be part of the process of bringing about this change to the industry.”

“When you think about companies with life-changing technologies, Medical 21 pretty much fits the blueprint,” says Scott Pantel, CEO of medtech market research firm Life Science Intelligence, an MFP strategic partner. “They’ve found a way to not only make bypass surgeries safer and cheaper, but also more accessible to patients. Stephen and I see huge potential here, and we’re committed to helping them secure the growth capital required for their next milestones.” 

Watch Medical 21, CEO, Manny Villafaña, Investor Presentation at LSI USA '22

Medical 21 will be among 100 vetted presenting companies attending the LSI Europe ’22 Emerging Medtech Summit in London taking place on September 21-24, 2022. In addition to company presentations, the event will feature panel sessions with investors, one-on-one meetings, and vast networking opportunities with leading medtech investors, strategics, and industry insiders. 

About Medical 21
Medical 21, Inc. is a developmental stage medical device company founded by Manny Villafaña, Ph.D.Sc., located in Minneapolis, Minnesota. Medical 21 is developing and intends to commercialize and market an artificial graft to bypass blockages in the heart. This revolutionary product is supported by a team that collectively possesses decades of experience in the successful development, manufacturing, sales, and marketing of medical products to the domestic and international healthcare markets. The Medical 21 artificial graft is not yet FDA approved or cleared. For investigational use only. Not yet available for commercial sale.

Medical 21 is considering an offering of securities exempt from registration under the Securities Act of 1933, but has not determined a specific exemption from registration it intends to rely on for the subsequent offer and sale of the securities.  No money or other consideration is being solicited, and if sent in response, will not be accepted.  No offer to buy the securities can be accepted and no part of the purchase price can be received until Medical 21 determines the exemption under which the offering is intended to be conducted and, where applicable, the filing, disclosure, or qualification requirements of such exemption are met.  A person's indication of interest involves no obligation or commitment of any kind.

About Medical Funding Professionals
Medical Funding Professionals is a registered investment advisor firm providing capital and cash flow planning solutions to the medical industry, including life sciences, biotech, medtech, and pharmaceutical sectors. Their Capital Planning Valuation Strategy™ (CPVS) ensures founders and key executives maintain control of their companies as they raise capital and grow. Medical Funding Professionals compliments its advisory services by providing further guidance on how to utilize the updated private company exemptions such as 506c for accredited investors and Reg A+ which allows a company to raise up to $75M from both accredited and non-accredited every 12 months.

About Life Science Intelligence
LSI is a medical technology-focused market intelligence & consulting company that helps medtech executives make informed strategic decisions by better understanding market dynamics, trends, opportunities and the competitive landscape.

Regulation A+ Disclaimer

This communication may be deemed to be a solicitation of interest under Regulation A under the Securities Act of 1933, in which case the following apply:

• No money or other consideration is being solicited, and if sent in response, will not be accepted;
• No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date;
• A person’s indication of interest involves no obligation or commitment of any kind; and 
• An offering statement, which would include a preliminary offering circular, has not yet been filed with the SEC.